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Abstract
Introduction: Spontaneous T cell responses against specific tumor-associated antigens (TAA) are
frequently detected in peripheral blood of tumor patients of various histiotypes. However, little is
known about whether these circulating, spontaneously occurring, TAA-reactive T cells influence
the clinical course of disease.
Methods:  Fifty-four HLA-A2 positive colorectal cancer patients had been analyzed for the
presence of T cell responses against epitopes derived from the TAA Ep-CAM, her-2/neu, and CEA
either by ELISPOT assay or by intracellular cytokine staining. Then, Kaplan-Meier survival analysis
was performed comparing T-cell-responders and T-cell-non-responders. For comparison, a group
of T-cell-non-responders was compiled stringently matched to T-cell-responders based on clinical
criteria and also analyzed for survival.
Results: Sixteen out of 54 patients had a detectable T cell response against at least one of the three
tested TAA. Two out of 21 patients (9.5%) with limited stage of disease (UICC I and II) and 14 out
of 33 patients (42.4%) with advanced disease (UICC III and IV) were T cell response positive.
Comparing all T-cell-responders (n = 16) and all T-cell-non-responders (n = 38), no survival
difference was found. In an attempt to reduce the influence of confounding clinical factors, we then
compared 16 responders and 16 non-responders in a matched group survival analysis; and again no
survival difference was found (p = 0.7).
Conclusion: In summary, we found no evidence that spontaneous peripheral T cell responses
against HLA-A2-binding epitopes of CEA, her-2/neu and Ep-CAM are a strong prognostic factor
for survival.
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Introduction
The importance of the immune system in containing
tumor growth is supported by animal studies and various
observations in humans [1,2]. These include increased
prevalence of certain tumors following immunosuppres-
sion as well as the demonstration, that the presence of int-
ralesional T cells is correlated with improved clinical
outcome in various solid tumors [1,3-6]. In particular in
CRC, the presence of CD8+ T cells within the tumor
microenvironment was significantly associated with a bet-
ter survival in several studies [3,7-9]. However, the anti-
gen-specificity of these cells was not determined. T cell
responses against specific tumor-associated antigens
(TAA) are frequently detected in the peripheral blood of
tumor patients [reviewed in [10]] of various histiotypes
including colorectal cancer [11], melanoma [12,13], acute
myeloid leukemia [14], breast cancer [15], neuroblastoma
[16], and head and neck cancer [17]. Data from selected
single patients suggest a favorable clinical course in
patients with peripheral, spontaneous TAA-directed T cells
[18,19]. However, this type of analysis does not allow
firm conclusions. The only study comparing clinical out-
come of patients with presence of antigen-specific
immune responses including natural as well as vaccine-
induced antibodies against melanoma antigen GM2
showed an improved survival in favor of immune
responders [20]. TAA-directed T cell responses can reliably
be induced using various vaccination approaches
[reviewed in [21]]. Several recent reports have found a cor-
relation between induction of a TAA-directed T cell
response by vaccination and clinical response [22-25].
Preliminary data also suggest a possibly favorable clinical
effect of vaccine-induced T cells in adjuvant vaccination
[26-29]. Taken together, these data lead to the question,
whether the presence of spontaneous TAA-specific T cells
might be a positive prognostic factor. So far, however, no
study has systematically compared survival data of
patients with and without presence of a spontaneous TAA-
directed T cell response.
In previous studies, we have demonstrated spontaneous T
cell responses against the TAA CEA, Ep-CAM, or her-2/neu
in peripheral blood of approximately 25% of colorectal
cancer patients [11,30]. These cells were identified in
functional T cell assays by antigen-induced IFNγ produc-
tion. More detailed analyses in some samples revealed a
CD3+ CD8+ IFNγ+ CD69+ CD45RA+ phenotype [11],
indicative of an effector T cell subset that is able to directly
mediate tumor cell lysis [19]. Spontaneous TAA-specific T
cells with the potential of effector cells should, theoreti-
cally, be capable of destroying tumor cells and thereby
lead to elimination of residual disease or prevent tumor
progression. To investigate whether a peripheral, sponta-
neous T cell response has an effect on the clinical outcome
of tumor patients, we analyzed survival data of CRC
patients with a TAA-directed T cell response and com-
pared these data with the clinical course of CRC patients
without detectable T cell response.
Patients, materials, and methods
Patient selection and T cell assays
After institutional review board approval and informed
consent, peripheral blood mononuclear cells from 132
patients with CRC in all stages of disease had been pro-
spectively collected and frozen for T cell analysis. All anal-
yses have been performed in compliance with the
Helsinki Declaration. Fifty-four patients were tested posi-
tive for HLA-A2 and were subsequently analyzed for the
presence of T cell responses against the HLA-A*0201 pre-
sented T cell epitopes Ep-CAM p263–271 [31], her-2/neu
p654–662 [32,33], and CEA p571–579 [34] either by
ELISPOT assay or by intracellular cytokine staining. HLA
analysis, ELISPOT, and intracellular cytokine staining
were performed as previously described [11,30]. Positive
responses were defined as previously described [11,30].
Survival analysis
First, we performed a Kaplan-Meier survival analysis com-
paring all T-cell-responders and all T-cell-non-responders.
Additionally, a two-sided log rank test was used to test sta-
tistical significance. Then, in an attempt to reduce the
influence of external factors, we compiled a patient group
from non-responders matching them to responders
according to the following criteria: UICC stage of disease,
gender, presence of clinically detectable tumor at time of
blood draw, duration of disease until blood draw, age at
first diagnosis, and previous therapy. Survival in both
groups was compared using Kaplan-Meier analysis and by
a two-sided log rank test. A level of p < 0.05 was consid-
ered significant. SPSS (11.5) software was used.
Results
Patients, T cell response, survival of responders and non-
responders
Fifty-four HLA-A2 positive CRC patients who had been
analyzed for T cell responses were included in this study
[11,30] and retrospectively analyzed for survival. The
overall survival rate was 66.7% at a median of 27.5
months follow-up after blood draw for T cell analysis. In
16 out of 54 patients a total number of 26 T cell responses
(between 10 and 1110 specific T cell per 106 PBMC)
against one of the three TAA Ep-CAM, her-2/neu, and CEA
had been detected. Comparing all responders (n = 16)
and all non-responders (n = 38), no survival difference
was found in a two-sided log rank test (p = 0.4; Fig. 1A). A
very slight trend toward better survival was found in favor
of non-responders, which is, however, far from being sta-
tistically significant. Since we have previously observed
that T cell responses occur more frequently in patients
with advanced stages of disease, we compared clinicalJournal of Translational Medicine 2005, 3:3 http://www.translational-medicine.com/content/3/1/3
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data for all patients; and found that among non-respond-
ers only 50% (19 out of 38) had clinical stage III or IV dis-
ease while 87.5% (14 out of 16) responding patients had
stage III or IV disease. Thus, the data on survival are possi-
bly based on a strong stage-related bias. Therefore, we sub-
sequently used an approach matching non-responders to
responders.
Survival in matched patient groups
Sixteen patients from the above group of 38 non-respond-
ers were matched with 16 responders to obtain two
groups comparable for potentially confounding clinical
factors, in particular stage of disease (see table 1). At the
time of the survival analysis 13 of the total of 32 (40.6%)
patients had died: seven T-cell-responders (n = 1 stage III,
Kaplan-Meier survival analyses of colorectal cancer patients based on their T cell response state Figure 1
Kaplan-Meier survival analyses of colorectal cancer patients based on their T cell response state. Dashed lines refer to T-cell-
responders, full lines refer to T-cell-non-responders, crosses mark censored cases. Time point 0 refers to the time of blood 
draw for T cell analysis. A. Two groups of CRC patients (total n = 54) were analyzed for survival after T cell analysis. One 
group had a spontaneous T cell response against the tumor associated antigens CEA, Ep-CAM, or her-2/neu (n = 16, dashed 
line). The other group had no T cell response against these antigens (n = 38, full line). No survival difference between the 
groups was found (log rank, p = 0.4). B. Two matched groups of CRC patients (total n = 32) were analyzed for survival after T 
cell analysis. One group had a spontaneous T cell response against tumor antigens CEA, Ep-CAM, or her-2/neu (n = 16, dashed 
line). The other group had no T cell response against these antigens and was selected by having similar clinical characteristics 
for stage, gender, presence of clinically detectable tumor at time of blood draw, duration of disease, age, and prior therapy (n 
= 16, full line). No survival difference was found (log rank, p = 0.7).
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n = 6 stage IV) and six T-cell-non-responders (n = 1 stage
III, n = 5 stage IV). All deaths were CRC-related. Median
time to death among T-cell-responders was 11 months,
among T-cell-non-responders 14.5 months. The calcu-
lated mean survival time after blood draw for patients
without T cell response was 37.0 months (± 4.8 SEM) with
a 95% confidence interval 27.5–46.5. Mean survival of T-
cell-responders was 40.2 months (± 6.5 SEM) with 95%
confidence interval of 27.5–52.9 (Fig. 1B). In a two-sided
log rank test, survival did not show a statistically signifi-
cant difference between responders and non-responders
(p = 0.7). Of note, one to two years after blood draw,
patients without T cell response had an up to 20% higher
survival rate (approx. 80% vs. approx 60%). These results
were, however, not significant. In a two-sided test with β
= 0.2, a survival difference of 70% could have been con-
sidered significant at a level of α = 0.05 in a population of
this size.
Discussion
In the present study, we analyzed the clinical course of
colorectal cancer patients with or without T cells reactive
against HLA-A2-binding epitopes of Ep-Cam, her-2/neu,
and CEA. No survival difference between T-cell-respond-
ers and T-cell-non-responders was found. This result has
to be interpreted cautiously due to the small number of
HLA-A2+ patients responding to the above antigens.
Obviously, these small numbers cause a high beta error.
Thus, this study is only a first indication that the tested
spontaneous T cell responses are not important prognos-
tic factors for survival.
The second limitation of our study is that the known rep-
ertoire of TAA as potentially important T cell targets in
CRC grows every year; and our T cell analysis included
only a fraction of potential epitopes. Various other CRC-
associated antigens, such as MUC1 or p53, and additional
MHC class I antigenic epitopes of CEA and her2-neu have
been described [summarized in [35]]. T cell responses
against antigens in addition to the ones tested here could
potentially play a role in immune surveillance of CRC.
Immune surveillance is understood as a complex process
in which T cells and tumor cells influence each other in
several ways ["immunoediting", [1]]. There are various
potential factors related to tumor cells as well as T cells
which may explain a lack of survival effect by TAA-specific
T cells. The frequency of TAA-specific T cells detected in
most patients was quite low in the range of 10 to 100 T
cells per 106 PBMC. These numbers may be too low to
control tumor growth especially in patients with a higher
tumor burden. Furthermore, a general T cell dysfunction
including anergic T cells and T cells with downregulated
CD3-zeta chains has been described in CRC patients
[36,37]. It is possible that the specific T cells detected in
the present study are functionally unable to destroy tumor
cells. This assumption, however, is not supported by our
previous finding that TAA-specific T cells have an effector
potential as analyzed in selected patients [11]. Since we
have analyzed peripheral blood, we do not know if the cir-
culating T cells have the potential to migrate to the tumor
site or compartments where CRC cells frequently migrate
to including lymph node, liver and bone marrow.
Furthermore, tumor cells may not be recognizable by
TAA-specific T cells. It has been shown that CRC cell lines
secrete immunosuppressive cytokines and that develop-
ment of T cell responses is impeded due to low HLA
Table 1: Patient characteristics
Peripheral spontaneous T cell response against 
TAA
Positive Negative (matched) Negative (total)
Number of patients 16 16 38
Age at first diagnosis, mean ± SD 61.2 ± 12.1 59.9 ± 9.1 60.8 ± 11.1
Male/Female 11/5 11/5 19/19
Duration of disease until T cell analysis (mean) 31.8 30.2 27.4
Stage (UICC) I 0 0 1 (2.6%)
II 2 (12.5%) 2 (12.5%) 18 (47.4%)
III 3 (18.8%) 3 (18.8%) 5 (13.2%)
IV 11 (68.8%) 11 (68.8%) 14 (36.8%)
Previous therapy CT 9 (56.3%) 12 (75%) 18 (47.4%)
RT 3 (18.8%) 4 (25%) 7 (18.4%)
Surgery 12 (75%) 14 (87.5%) 30 (78.9%)
Patients without evidence of tumor at time of blood draw 4 (25%, 2 II, 2 III) 4 (25%, 2 II, 2 III) 17 (45%, 13 II, 3 III, 1 IV)
Time from blood draw until death or last contact, mean 
± SD
28.1 ± 19.2 27.4 ± 15.0 25.7 ± 14.0
Abbreviations: SD standard deviation, CT chemotherapy (5-FU + folic acid, in few cases plus Irinotecan), RT radiotherapyJournal of Translational Medicine 2005, 3:3 http://www.translational-medicine.com/content/3/1/3
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expression and lack of intercellular adhesion molecule-1
(ICAM-1) and HLA-DR [38,39]. This is especially relevant
considering the fact that TAA-specific T cell responses in
peripheral blood are more frequently detectable in
advanced stages of CRC [11,40], as well as other tumors
[40,41]. These data led to the hypothesis that metastasiz-
ing of tumor cells to lymph nodes is a prerequisite for the
development of circulating T cell responses [11,42]. Fur-
thermore, the presence of TAA-directed T cell responses
may have selected immune escape tumor variants. A
broad variety of tumor escape mechanisms, such as anti-
gen loss or loss of HLA expression, is described in various
clinical conditions [43]. It is possible that we encounter
similar mechanisms in the present study since malignant
cells had grown in vivo during the presence of specific T
cell responses. Finally, the role of suppressor and regula-
tory T cells in this specific context is unknown.
Taken together, no evidence was found that peripheral,
spontaneous T cell responses against HLA-A*0201-bind-
ing epitopes of CEA, Ep-CAM, or her-2/neu influence sur-
vival of CRC patients. Since the low patient number limits
the conclusion, further studies should investigate more
patients, more detailed function and migratory pattern of
spontaneous T cell responses as well as the genetic profile
of the tumor; and consider a broader antigen and epitope
repertoire. These studies could have implications for vac-
cination therapy as we learn more about why immune
surveillance may fail to control tumors and if the presence
of a natural T cell response may impact on the efficacy of
a vaccine.
Abbreviations
CEA carcinoembryonic antigen, CRC, colorectal carci-
noma; ELISPOT, enzyme-linked immunospot; IFNγ,
Interferon-γ; HLA, human leukocyte antigen; PBMC,
peripheral blood mononuclear cells, TAA, tumor associ-
ated antigen.
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